Launch the first rare disease program, for propionic acidemia
Deadline not yet reached (796 days left)
- Announced
- 5 Jan 2026
- Due
- 31 Dec 2028
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“By 2028, we also expect to launch our first rare disease program in PA, supported by data expected in 2026.”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2028.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Propionic acidemia rare disease therapeutic launch
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-MRNA-006252 · Corrections policy